Crohn's & Colitis 360最新文献

{"title":"Treatment outcomes of prolonged induction or re-escalation dosing of upadacitinib in patients with inflammatory bowel disease.","authors":"Ellen Axenfeld, Vasantham Chaudhary, Joseph W Clinton, Michael Frohlinger, Lauren George, Raymond K Cross, Jordan E Axelrad","doi":"10.1093/crocol/otag021","DOIUrl":"https://doi.org/10.1093/crocol/otag021","url":null,"abstract":"<p><strong>Background: </strong>Proposed treatment algorithms favor the use of upadacitinib in medically refractory Crohn's disease (CD) and ulcerative colitis (UC). There has not yet been data published regarding efficacy of prolonged induction in CD or the efficacy of re-escalation to induction dosing in patients with either CD or UC. The aim of this study was to evaluate the real-world efficacy and safety of prolonged and/or re-escalation upadacitinib therapy in patients with inflammatory bowel disease (IBD) and prior inadequate response to standard upadacitinib treatment.</p><p><strong>Methods: </strong>This was a retrospective, dual-center study of the efficacy of prolonged induction or re-escalation of upadacitinib in patients with IBD with prior inadequate response to standard upadacitinib treatment.</p><p><strong>Results: </strong>Fifty-five patients met eligibility criteria. Thirty-nine (70.9%) persisted on upadacitinib therapy while 16 (29.1%) met the primary endpoint for upadacitinib failure. Of those that had comparative objective data, 62.5% had improvement in endoscopic activity, 100% had normalization of an elevated CRP, and 83.3% experienced a decrease in FCP by >50%. There were no new safety signals.</p><p><strong>Conclusion: </strong>Over two-thirds of patients met the primary endpoint of persistence on therapy without requiring surgery, steroids, or additional biologic/small molecule inhibitor during follow-up. In a subset of patients who had adequate baseline and follow up objective data, the majority of patients had improvement in mucosal healing, decrease by 50% in FCP, and normalization of CRP. This study shows promising results that prolonged upadacitinib induction or dose re-escalation may improve clinical outcomes in a medically refractory patient population.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 2","pages":"otag021"},"PeriodicalIF":1.8,"publicationDate":"2026-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13134379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Providing care at a most vulnerable time.","authors":"Paula Prieto Tizzard, Shervin Rabizadeh, Joel R Rosh","doi":"10.1093/crocol/otag030","DOIUrl":"https://doi.org/10.1093/crocol/otag030","url":null,"abstract":"","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 2","pages":"otag030"},"PeriodicalIF":1.8,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13131972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of ABBV-154 in patients with moderately to severely active Crohn's disease: a phase 2b, randomized, double-blind, placebo-controlled trial.","authors":"Walter Reinisch, Laurent Peyrin-Biroulet, Geert D'Haens, Andreas Sturm, Jaclyn K Anderson, Izabella Messina, Dilek Arikan, Alissa Zimmerman-Bennett, Julie Parmentier, Tian Feng, Ronilda D'Cunha, Andreas Lazar, Edouard Louis","doi":"10.1093/crocol/otag014","DOIUrl":"10.1093/crocol/otag014","url":null,"abstract":"<p><strong>Background: </strong>ABBV-154 is an antibody-drug conjugate of adalimumab and a proprietary glucocorticoid receptor modulator. This phase 2b randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of ABBV-154 versus placebo in patients with moderately to severely active Crohn's disease who had inadequate response to or were intolerant of prior biologic therapy.</p><p><strong>Methods: </strong>Patients were randomized 1:1:1:1:1 to ABBV-154 induction groups: 150 mg IV at week 0, then 80 mg SC at week 2 and every other week (EOW); 300 mg IV at week 0, then 230 mg SC at week 2 and EOW; 600 mg IV at week 0, then 530 mg SC at week 2 and EOW; 600 mg IV at week 0, then 530 mg SC at weeks 4 and 8, and placebo at weeks 2, 6, and 10; or placebo. The primary endpoint was achievement of endoscopic response per SES-CD by central review at week 12. Adverse events were monitored throughout.</p><p><strong>Results: </strong>Of 265 planned patients, 106 were randomized and treated until completion, discontinuation, or early study termination by the sponsor. At week 12, greater proportions of patients treated with ABBV-154 achieved endoscopic response versus placebo (7.1%, 33.3%, 28.6%, and 27.3% across the induction groups vs. 0%; data reported as observed). Adverse events were comparable across all ABBV-154 groups and slightly higher than placebo through week 12.</p><p><strong>Conclusions: </strong>ABBV-154 was well tolerated and demonstrated proof-of-concept for efficacy in patients with moderately to severely active Crohn's disease. Results should be interpreted with caution due to early study termination.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 2","pages":"otag014"},"PeriodicalIF":1.8,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099389/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and prevalence of immune-mediated extraintestinal manifestations in pediatric inflammatory bowel disease: a systematic review and meta-analysis.","authors":"Ruben J Colman, Sudheer K Vuyyuru, Virginia Solitano, John K MacDonald, Jessica Le, Amanda Ricciuto, Roberta Berard, Javed A Mohammed, Christopher Ma, Vipul Jairath, Eileen Crowley","doi":"10.1093/crocol/otag024","DOIUrl":"10.1093/crocol/otag024","url":null,"abstract":"<p><strong>Background: </strong>Immune-mediated extraintestinal manifestations (IM-EIMs) are common in pediatric inflammatory bowel disease (pIBD). This systematic review and meta-analysis aimed to summarize the incidence and prevalence of IM-EIMs in pIBD.</p><p><strong>Methods: </strong>MEDLINE, EMBASE, CENTRAL, and clinicaltrials.gov were searched up to May 6, 2024, for studies that included pIBD (2-17 years) patients diagnosed with IM-EIMs. Primary outcomes included the incidence and prevalence of IM-EIMs among pIBD. Meta-analysis included pooled proportions of IM-EIMs using DerSimonian-Laird random-effects model.</p><p><strong>Results: </strong>The pooled proportion of IM-EIMs overall was 10% (95% CI, 8%-12%; I² = 97.2%) among 65 pIBD studies (35 343 patients). The pooled proportion of IM-EIMs was 10% (95% CI, 7%-13%; I² = 94.8%) among 37 Crohn's disease (CD) studies (7657 patients), compared to 11% (95% CI, 7%-15%; I² = 93.3%) among 39 ulcerative colitis (UC) studies (4698 patients). Enthesitis was the highest reported individual IM-EIM (23%, 95% CI, 4%-50%; I² = 94.7%) in pIBD. Arthritis was the second highest reported individual IM-EIM (8%, 95% CI, 6%-10%; I² = 96%) in pIBD, followed by primary sclerosing cholangitis (PSC) in UC (5%, 95% CI, 4%-7%; I² = 81%). Uveitis, pyoderma gangrenosum, autoimmune hepatitis, and PSC in CD were the lowest reported IM-EIMs at 1% or less. The largest difference in proportions between IBD phenotypes was PSC, which was 4% higher in UC than CD.</p><p><strong>Conclusions: </strong>While musculoskeletal manifestations are common, fewer than 5% of pIBD patients experience ophthalmological, dermatological, and liver IM-EIMs. The small number of studies resulted in significant methodological and statistical heterogeneity. Multicenter collaborative efforts are needed to systematically describe the epidemiology of IM-EIMs in pIBD.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 2","pages":"otag024"},"PeriodicalIF":1.8,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation significantly alters mucosal transcriptomic signatures in pediatric inflammatory bowel disease.","authors":"Alexander Schnell, Xinyi Wei, Jan Bossenz, Iryna Manuilova, Jan Christoph, Ida Allabauer, Merle Classen, Adrian P Regensburger, Joachim Woelfle, Ramona Erber, André Hoerning","doi":"10.1093/crocol/otag023","DOIUrl":"10.1093/crocol/otag023","url":null,"abstract":"<p><strong>Objectives and study: </strong>Crohn's disease (CD) and ulcerative colitis (UC) share common features of inflammation to a greater extent in children than in adults. However, histopathological scoring systems of mucosal inflammation are usually available only for either one of these entities. The IBD-DCA score is the first of its kind to incorporate both into one scoring system but still lacks validation in pediatric IBD.</p><p><strong>Methods: </strong>An existing data of a multiplexed gene expression analysis of mucosal biopsies of 25 patients diagnosed with either CD (<i>n</i> = 16) or UC (<i>n</i> = 9) were evaluated according to the IBD-DCA score for distribution (D0-2), chronicity (C0-2) and activity (A0-2) of inflammation by an experienced pathologist. The scoring results were used to stratify the degree of mucosal inflammation of these patients into either low (0-3) or high (4-6) DCA scores. Subsequently, analysis for differentially expressed genes (DEG) between the low and high inflammation group was performed.</p><p><strong>Results: </strong>Scoring revealed 7 low and 9 high DCA samples for CD, whereas for UC only high DCA were scored. DEG analysis revealed 130 upregulated genes in the high DCA group compared to the low DCA group. 11 genes were identified as hub genes playing a pivotal role in immune regulation, among those several cyto- or chemokines (IL1B, CCL20, CXCL1/2), costimulatory receptors (IL2RA, CD80, TLR2) and modulatory proteins like PD-L1 and IDO1.</p><p><strong>Conclusion: </strong>Our results indicate that inflammatory activity rather as assessed by the IBD-DCA score rather than the underlying disease entity significantly alters the transcriptomic signature in mucosal specimens of pediatric IBD patients.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 2","pages":"otag023"},"PeriodicalIF":1.8,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influenza vaccine uptake among patients with inflammatory bowel disease: comparable outcomes between telemedicine and in-person care.","authors":"Mazen Almasry, Trevor L Schell, Luke Richard, Francis A Farraye, Mary S Hayney, Freddy Caldera","doi":"10.1093/crocol/otag022","DOIUrl":"10.1093/crocol/otag022","url":null,"abstract":"<p><strong>Background: </strong>Patients with inflammatory bowel disease (IBD) receiving immunosuppressive therapies are at increased risk of vaccine-preventable diseases, including influenza. Despite recommendations for annual influenza vaccination, uptake remains suboptimal. The COVID-19 pandemic prompted a surge in telemedicine (Tele-M) use, raising concerns about its impact on vaccination rates due to reduced in-person interactions. This study aimed to assess the impact of IBD-specific Tele-M on influenza vaccine uptake and identify predictors of vaccination in patients with IBD.</p><p><strong>Methods: </strong>This single-center retrospective study evaluated influenza vaccine uptake among adult patients with IBD seen between September 2021 and April 2022. Patients were categorized into two groups: Tele-M only and ≥1 in-person visit. Vaccination status was confirmed using the Wisconsin Immunization Registry. Primary outcome was influenza vaccination frequency by visit type, while secondary outcomes evaluated the impact of Tele-M on other vaccinations and predictors of influenza vaccine uptake.</p><p><strong>Results: </strong>Among 547 patients, 53.2% received Tele-M only, and 46.8% had ≥1 in-person visit. Influenza vaccine uptake was similar between the Tele-M only and ≥1 in-person visit groups (69.0% vs. 75.1%, respectively, <i>P</i> = .11). The uptake of pneumococcal, hepatitis B, and zoster vaccines was also comparable. Predictors of higher influenza vaccine uptake included age ≥65, female sex, receipt of ≥3 COVID-19 vaccines, and previous influenza vaccination.</p><p><strong>Conclusions: </strong>IBD-specific Tele-M did not adversely affect influenza vaccine uptake among patients with IBD. These findings highlight the importance of ensuring vaccination compliance irrespective of healthcare delivery modes. Collaboration among healthcare providers is crucial to improve vaccination rates in patients with IBD.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 2","pages":"otag022"},"PeriodicalIF":1.8,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147765089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Child and parent perspectives in IBD management: a literature review and qualitative study.","authors":"Jennifer C deBruyn, Lara Hart, Gail MacKean, Nicole Staples, Amy Lee, Karen V MacDonald, Deborah A Marshall","doi":"10.1093/crocol/otag020","DOIUrl":"10.1093/crocol/otag020","url":null,"abstract":"<p><strong>Background: </strong>The therapeutic landscape and treatment goals for pediatric inflammatory bowel disease (IBD) continue to evolve. However, there remains a paucity of literature capturing the experiences and preferences of children with IBD and their parents on IBD management.</p><p><strong>Methods: </strong>We conducted a literature review and qualitative study to describe perspectives and preferences of children with IBD and their parents regarding IBD treatment, treatment goals, and decision-making in IBD management. Articles were identified in MEDLINE and key study characteristics and findings were summarized to inform qualitative interviews. Children with IBD (11-18 years of age) and their parents were recruited through purposive sampling from a gastroenterology clinic for semi-structured telephone interviews until code saturation was reached in thematic analysis.</p><p><strong>Results: </strong>In the literature review, 207 records were identified with nine studies ultimately included. Important aspects of IBD treatment included treatment efficacy, symptomatic improvements, and associated risks and side effects. Parents of children with IBD were concerned about the risks and preferred treatments with fewer long-term adverse effects; adolescents with IBD focused on immediate quality-of-life and short-term benefits. Ten parents and nine children with IBD (2.7-7.9 years disease duration) participated in interviews. Five major themes emerged: (1) overall impact of IBD and its management; (2) IBD treatment goals; (3) considerations for IBD management decisions on treatment; (4) considerations for IBD management decision on testing; and (5) shared decision-making.</p><p><strong>Conclusions: </strong>Our findings highlight how children and parents contextualize the importance of IBD management within their lives, and draw attention to the need for personalized, patient-centered care and meaningful shared decision-making.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 1","pages":"otag020"},"PeriodicalIF":1.8,"publicationDate":"2026-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13019527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early proactive therapeutic drug monitoring with ustekinumab therapy in pediatric Crohn's disease: data from the prospective Canadian children IBD network.","authors":"Amanda Ricciuto, Hayley E McKay, Jennifer C deBruyn, Eileen Crowley, Peter C Church, Hien Q Huynh, Anthony R Otley, Ayub Shaikh, David R Mack, Nicholas Carman, Wael El-Matary, Rilla Schneider, Eytan Wine, Thomas D Walters, Anne M Griffiths","doi":"10.1093/crocol/otag019","DOIUrl":"10.1093/crocol/otag019","url":null,"abstract":"<p><strong>Background: </strong>Ustekinumab dosing information for pediatric Crohn's disease (CD) is limited.</p><p><strong>Aims: </strong>To examine ustekinumab pharmacokinetic and effectiveness data in a largely bio-naïve cohort, focusing on early (week 8) levels.</p><p><strong>Methods: </strong>Children in the prospective Canadian Children IBD Network initiating intravenous (IV) ustekinumab for CD with a week 8 level were evaluated. Disease activity was assessed by corticosteroid-free clinical remission (CSFR), biochemical CSFR, and mucosal healing (MH) by colonoscopy or fecal calprotectin <150 µg/g beyond 16 weeks. We compared drug levels by weight group (</≥40kg) and outcome, using receiver-operating characteristic (ROC) curves to identify optimal week 8 levels.</p><p><strong>Results: </strong>Amongst 58 children (19 < 40 kg, 81% bio-naïve, median (interquartile range [IQR]) follow-up 11.5 [7.6-16.0] months), the IV loading dose for those <40kg (median 9.1 [8.6-10.2] mg/kg; 253 (239-268) mg/m²) was greater than for those ≥40kg (median 6.1 [5.4-6.5] mg/kg; 218 ([78-237] mg/m², <i>P</i> < .001). However, week 8 levels were similar (<i>P</i> = .26). This was most striking in those with low albumin. Of 34/58 (59%) without escalation to 4 weekly dosing, 43%, 35%, and 19% exhibited CSFR, biochemical CSFR, and MH, respectively, during established maintenance. Median week 8 levels were roughly 5-6 µg/g vs 7-10 µg/g in patients not achieving vs achieving favorable outcomes, while ROC analysis indicated levels 8-9 µg/mL were associated with improved outcomes.</p><p><strong>Conclusions: </strong>Children <40 kg required more IV ustekinumab (median 9 mg/kg; 250 mg/m²) to achieve similar week 8 levels as children ≥40kg receiving conventional adult 6 mg/kg weight-tiered induction. Higher week 8 levels were associated with favorable later outcomes.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 1","pages":"otag019"},"PeriodicalIF":1.8,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13016668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147519842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of mirikizumab on patient-reported outcomes and quality of life in patients with Crohn's disease: results from the phase 2 SERENITY study.","authors":"Vipul Jairath, Theresa Hunter Gibble, Laurent Peyrin-Biroulet, Bruce E Sands, Fumihito Hirai, Toshifumi Hibi, Edward V Loftus, Raymond K Cross, Marijana Protic, Lai Shan Chan, Nathan Morris, Kristina Traxler, David T Rubin","doi":"10.1093/crocol/otag018","DOIUrl":"10.1093/crocol/otag018","url":null,"abstract":"<p><strong>Background: </strong>Mirikizumab is an anti-IL23p19 antibody that has shown efficacy in treating moderately to severely active Crohn's disease in a phase 2 study. We studied mirikizumab's impact on quality of life in these patients.</p><p><strong>Methods: </strong>Patients (<i>N</i> = 191) were randomized using a 2:1:1:2 allocation across 4 treatment arms (placebo, 200 mg, 600 mg, or 1000 mg mirikizumab, administered intravenously every 4 weeks [week 0, week 4, and week 8]). Patients who received mirikizumab and achieved ≥1-point improvement in Simple Endoscopic Score for Crohn's Disease at week 12 were rerandomized into double-blind maintenance to continue treatment with either intravenous assignment or 300 mg mirikizumab subcutaneous every 4 weeks to week 52. Non-improvers or placebo patients received 1000 mg mirikizumab until week 52. Patients with clinical benefit from the maintenance period received 300 mg subcutaneously to week 104. Quality of life and patient-reported outcomes were evaluated with the Inflammatory Bowel Disease Questionnaire, 36-Item Short-Form Health Survey Mental Component Summary and Physical Component Summary, Patient's Global Rating of Severity, and Abdominal Pain Numeric Rating Scale. Quality of life measures were evaluated up to week 104 and analyzed with a mixed model for repeated measures up to week 12 and descriptively afterward.</p><p><strong>Results: </strong>At week 12, all mirikizumab groups had improved quality of life and patient-reported outcome scores compared to placebo. These improvements were sustained through week 52 and week 104.</p><p><strong>Conclusions: </strong>Treatment with mirikizumab was associated with significantly improved quality of life and patient-reported disease severity sustained through week 104 in patients with moderately-to-severely active Crohn's disease in this phase 2 study (NCT02891226).</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 1","pages":"otag018"},"PeriodicalIF":1.8,"publicationDate":"2026-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13017000/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transabdominal intestinal ultrasound versus transmural histopathological findings in severe ulcerative colitis requiring colectomy.","authors":"Hiromu Morikubo, Jun Miyoshi, Akimasa Hayashi, Haruka Komatsu, Hiromi Yonezawa, Minoru Matsuura, Junji Shibahara, Tadakazu Hisamatsu","doi":"10.1093/crocol/otag017","DOIUrl":"10.1093/crocol/otag017","url":null,"abstract":"<p><strong>Background: </strong>Transabdominal intestinal ultrasound (IUS) is a promising, non-invasive tool for monitoring ulcerative colitis (UC). This modality has the advantage of assessing intestinal inflammation transmurally, suggesting that UC can be considered a transmural disease. Determining what transabdominal IUS findings indicate in terms of histopathology would improve its value in assessing disease activity. However, associations between sonographic and histopathological findings have not yet been established for active UC. To address this gap, we investigated patients with active UC who underwent colectomy following IUS examination.</p><p><strong>Methods: </strong>Patients who underwent total colectomy for severe active UC within 1 week of undergoing transabdominal IUS at our facility between December 2020 and March 2023 were consecutively included in this study. Sonographic and histopathological findings were compared for each colonic segment in these patients.</p><p><strong>Results: </strong>Four patients underwent IUS 3-6 days before colectomy, which was performed due to insufficient response to medical treatment. IUS findings, particularly loss of bowel stratification and increased color Doppler signals, were associated with severe inflammation and vascular proliferation in the transmural colon, including the subserosa. Thickened muscularis propria was also observed in inflamed colonic segments; this may have contributed to the increased bowel wall thickness according to IUS.</p><p><strong>Conclusions: </strong>This is the first report comparing IUS findings and transmural pathological features in active UC. It provides an imaging atlas and clinical insights into the role of IUS in determining transmural histopathological inflammatory status in patients with active UC.</p>","PeriodicalId":10847,"journal":{"name":"Crohn's & Colitis 360","volume":"8 1","pages":"otag017"},"PeriodicalIF":1.8,"publicationDate":"2026-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12985694/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147466488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}